Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.56)
# 3,842
Out of 4,829 analysts
55
Total ratings
26.53%
Success rate
-32.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $3.62 | +203.87% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $10.38 | +198.65% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.17 | +1,523.93% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $4.43 | +374.04% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $1.82 | +174.73% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.16 | +1,279.31% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $0.46 | +2,079.12% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $6.34 | +294.32% | 2 | May 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $1.41 | +14,084.40% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $0.88 | +693.20% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.21 | +726.45% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $9.50 | +531.58% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.30 | +1,892.69% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.80 | +108.33% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.73 | +32,980.63% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $6.49 | +2,704.31% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.24 | +33,372.80% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.81 | +611.74% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.45 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.05 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.10 | +445.45% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.99 | +133.59% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $6.23 | +168,439.33% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.53 | +2,318.30% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $0.59 | +3,297.32% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $527.78 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $58.98 | +50.90% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $115.71 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.78 | +127,353.48% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.80 | +18,566.67% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.17 | +467.82% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $3.62
Upside: +203.87%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $10.38
Upside: +198.65%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.17
Upside: +1,523.93%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $4.43
Upside: +374.04%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $1.82
Upside: +174.73%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.16
Upside: +1,279.31%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $0.46
Upside: +2,079.12%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $6.34
Upside: +294.32%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $1.41
Upside: +14,084.40%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $0.88
Upside: +693.20%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.21
Upside: +726.45%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $9.50
Upside: +531.58%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.30
Upside: +1,892.69%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.80
Upside: +108.33%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.73
Upside: +32,980.63%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $6.49
Upside: +2,704.31%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.24
Upside: +33,372.80%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $2.81
Upside: +611.74%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.45
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.10
Upside: +445.45%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.99
Upside: +133.59%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $6.23
Upside: +168,439.33%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $1.53
Upside: +2,318.30%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $0.59
Upside: +3,297.32%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $527.78
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $58.98
Upside: +50.90%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $115.71
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.78
Upside: +127,353.48%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.80
Upside: +18,566.67%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.17
Upside: +467.82%